The Senate Finance Committee today held a hearing for Alex Azar, President Trump’s nominee for secretary of Health and Human Services. Azar, former president of Lilly USA and deputy HHS secretary under the George W. Bush administration, faced a number of questions from senators about his ties to the pharmaceutical industry and how he would tackle high drug prices. If confirmed, Azar said he would focus his efforts on addressing the high cost of drugs; making health care more affordable, available and “tailored to what individuals want and need in their care”; harnessing “the power of Medicare to shift the focus in our health care system from paying for procedures and sickness to paying for health and outcomes”; and tackling “the scourge of the opioid epidemic.” Tom Price, M.D., resigned as HHS secretary last September. Deputy Secretary Eric Hargan has been serving as acting secretary.

Related News Articles

Headline
The AHA Aug. 28 published a blog responding to a series of reports from the Paragon Health Institute alleging large-scale “fraud” in health care, this time…
Blog
Public
The Paragon Health Institute has published a series of new reports once again alleging large-scale “fraud” in health care. This time their target is enrollment…
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
A KFF analysis published Aug. 20 provides a state-by-state allocation of Congressional Budget Office estimates that 10 million people could be uninsured by…
Headline
The Centers for Medicare & Medicaid Services today announced a nationwide initiative aimed at reinforcing eligibility standards for Medicaid and the…
Headline
The Centers for Medicare & Medicaid Services has issued the 2025-2026 Medicaid Managed Care Rate Development Guide for states to use when setting managed…